Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marzia Capelletti

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Cancer Research|June 7, 2015
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2Junko Tanizaki, Dalia Ercan, Marzia Capelletti, et al.
Cancer Research|October 30, 2010
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancersTakaaki Sasaki, Katsuhiro Okuda, Wei Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2011
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaMai He, Marzia Capelletti, Khedoudja Nafa, et al.
Clinical Lung Cancer|April 15, 2025
Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted TherapiesSarah Waliany, Yin P Hung, Fawzi Abu Rous, et al.
Cancer Research|August 19, 2015
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase InhibitionMargaret Soucheray, Marzia Capelletti, Inés Pulido, et al.
Nature|December 25, 2009
Novel mutant-selective EGFR kinase inhibitors against EGFR T790MWenjun Zhou, Dalia Ercan, Liang Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancerMarcello Tiseo, Marzia Capelletti, Giuseppe De Palma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancerMaura Loprevite, Marcello Tiseo, Maurizio Chiaramondia, et al.
Cell|January 17, 2018
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRASChiara Ambrogio, Jens Köhler, Zhi-Wei Zhou, et al.
Blood|October 28, 2018
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patientsRomanos Sklavenitis-Pistofidis, Marzia Capelletti, Chia-Jen Liu, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Cancer Research|June 7, 2015
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2Junko Tanizaki, Dalia Ercan, Marzia Capelletti, et al.
Cancer Research|October 30, 2010
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancersTakaaki Sasaki, Katsuhiro Okuda, Wei Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2011
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaMai He, Marzia Capelletti, Khedoudja Nafa, et al.
Clinical Lung Cancer|April 15, 2025
Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted TherapiesSarah Waliany, Yin P Hung, Fawzi Abu Rous, et al.
Cancer Research|August 19, 2015
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase InhibitionMargaret Soucheray, Marzia Capelletti, Inés Pulido, et al.
Nature|December 25, 2009
Novel mutant-selective EGFR kinase inhibitors against EGFR T790MWenjun Zhou, Dalia Ercan, Liang Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancerMarcello Tiseo, Marzia Capelletti, Giuseppe De Palma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancerMaura Loprevite, Marcello Tiseo, Maurizio Chiaramondia, et al.
Cell|January 17, 2018
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRASChiara Ambrogio, Jens Köhler, Zhi-Wei Zhou, et al.
Blood|October 28, 2018
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patientsRomanos Sklavenitis-Pistofidis, Marzia Capelletti, Chia-Jen Liu, et al.
Pageof 6